Pancreatic Cancer Research

ResearcherHumanitas UniversityActive in the last 2 years

Giovanni Luigi Capretti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9429-3008; OpenAlex author ID A5003259856, A5047578711. Sources: OpenAlex.

Their work

Papers
32 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
103
Papers, trials and grants by year

2016: 3 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 4 papers · 2023: 8 papers · 2024: 6 papers · 2025: 2 papers · 2026: 3 papers

Papers 32

  1. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  2. Metabolomic profiling of pancreatic juice: a potential prognostic tool for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.suronc.2026.102456↗
  3. Multinucleated Giant Cells in Human Pancreatic Cancer Are a Distinct Macrophage Population Undergoing a DNA Damage Response and Associated with an Aggressive T… Co-author DOI 10.1158/2326-6066.cir-25-1602↗
  4. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  5. Pancreatic cancer and long survivors: a survey of Italian society of oncological surgery (SICO). Co-author DOI 10.1007/s13304-024-02039-3↗
  6. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  7. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  8. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  9. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  10. Delta Radiomic Features Predict Resection Margin Status and Overall Survival in Neoadjuvant-Treated Pancreatic Cancer Patients. Co-author DOI 10.1245/s10434-023-14805-5↗
  11. Integrating metabolic profiling of pancreatic juice with transcriptomic analysis of pancreatic cancer tissue identifies distinct clinical subgroups. Co-author DOI 10.3389/fonc.2024.1405612↗
  12. Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis? Co-author DOI 10.1007/s13304-023-01628-y↗
  13. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  14. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  15. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  16. Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective,… Co-author DOI 10.3389/fnut.2023.1065294↗
  17. Independent effect of fat-to-muscle mass ratio at bioimpedance analysis on long-term survival in patients receiving surgery for pancreatic cancer. Co-author DOI 10.3389/fnut.2023.1118616↗
  18. Corrigendum: Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: a r… Co-author DOI 10.3389/fnut.2023.1212436↗
  19. Early Recurrence after Upfront Surgery for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol30040282↗
  20. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival. First author DOI 10.1016/j.dld.2021.06.006↗
  21. Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2022.05.006↗
  22. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  23. Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreati… Co-author DOI 10.3390/cancers14112653↗
  24. Resectability of Pancreatic Cancer Is in the Eye of the Observer: A Multicenter, Blinded, Prospective Assessment of Interobserver Agreement on NCCN Resectabili… First author DOI 10.1097/as9.0000000000000087↗
  25. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  26. Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells. First author DOI 10.1158/2326-6066.cir-19-0403↗
  27. Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma. Co-author DOI 10.3791/61687↗
  28. Thrombosis of the dorsal vein of the penis as first clinical presentation of pancreatic cancer metastatic to the penis. Co-author DOI 10.1177/0300891619849273↗
  29. Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium. Co-author DOI 10.1245/s10434-018-6705-1↗
  30. Overuse of surgery in patients with pancreatic cancer. A nationwide analysis in Italy. First author DOI 10.1016/j.hpb.2015.11.005↗
  31. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2015.1085147↗
  32. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Co-author DOI 10.1136/gutjnl-2015-309193↗

Closest collaborators

The 25 strongest of 103 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alessandro Zerbi · 18 shared papers, 2016–2026 · strength 2.53
  2. Gennaro Nappo · 10 shared papers, 2020–2026 · strength 1.58
  3. Federica Marchesi · 8 shared papers, 2016–2026 · strength 1.08
  4. Francesca Gavazzi · 8 shared papers, 2016–2026 · strength 1.05
  5. Marialuisa Barbagallo · 6 shared papers, 2020–2026 · strength 0.99
  6. Silvia Bozzarelli · 5 shared papers, 2022–2026 · strength 0.88
  7. Greta Donisi · 5 shared papers, 2020–2026 · strength 0.79
  8. Roberto Salvia · 5 shared papers, 2021–2025 · strength 0.67
  9. Riccardo Casadei · 4 shared papers, 2021–2025 · strength 0.52
  10. Giuseppe Malleo · 4 shared papers, 2021–2023 · strength 0.51
  11. Luca Vittorio Gianotti · 4 shared papers, 2021–2023 · strength 0.51
  12. Nina Cortese · 5 shared papers, 2016–2024 · strength 0.47
  13. Carlo Ingaldi · 3 shared papers, 2023–2025 · strength 0.42
  14. Marta Sandini · 3 shared papers, 2023 · strength 0.42
  15. Claudio Bassi · 3 shared papers, 2023 · strength 0.42
  16. Salvatore Paiella · 3 shared papers, 2023 · strength 0.42
  17. Paola Allavena · 4 shared papers, 2016–2022 · strength 0.30
  18. Marco Erreni · 2 shared papers, 2020–2026 · strength 0.30
  19. Silvia Carrara · 2 shared papers, 2022 · strength 0.30
  20. Elena Desiato · 1 shared paper, 2026 · strength 0.28
  21. Matteo De Pastena · 2 shared papers, 2023 · strength 0.26
  22. Darío Gregori · 2 shared papers, 2023 · strength 0.26
  23. Erica Secchettin · 2 shared papers, 2023 · strength 0.26
  24. Ilaria Trestini · 2 shared papers, 2023 · strength 0.26
  25. Giulia Angela Zamboni · 2 shared papers, 2023 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.